This document reflects discussions from a multi-disciplinary roundtable on the possible role of renal denervation (RDN) as a therapeutic option to complement medical therapy and lifestyle interventions for patients with uncontrolled hypertension. The paper outlines consensus view on issues related to blood pressure control and associated risk, evaluation, and treatment pathways for hypertension, RDN safety and effectiveness, and how RDN may be incorporated into clinical practice. The expert panel consisted of hypertension specialists, nephrologists, general cardiologists, and interventional cardiologists. The roundtable was co-sponsored by SCAI and the National Kidney Foundtation.

All Authors: David E. Kandzari, MD, FSCAI; Raymond R. Townsend, MD; George Bakris, MD; Jan Basile, MD; Michael J. Block, MD; Debbie L. Cohen, MD; Cara East, MD; Keith C. Ferdinand, MD; Naomi Fisher, MD; Ajay Kirtane, MD, FSCAI; David P. Lee, MD, FSCAI; Gary Puckrein, PhD; Florian Rader, MD, MSc; Joseph A. Vassalotti, MD; Michael A. Weber, MD; Kerry Willis, MD; and Eric Secemsky, MD, FSCAI.